AstraZeneca enters three-year license agreement with Owkin for K Pro agentic AI platform

AstraZeneca (LSE/NYSE: AZN) has entered a three-year license agreement with Owkin, a privately held AI company founded in 2016 and headquartered across New York and Paris, covering K Pro, Owkin's agentic AI platform described by the company as an AI scientist for biopharma decision-making. Under the arrangement, Owkin will develop bespoke AI agents integrated into AstraZeneca's internal IT infrastructure, with initial capabilities focused on competitive intelligence and landscape forecasting for specific pharmaceutical targets, assets, and clinical trials. Financial terms were not disclosed.

K Pro is described by Owkin as an agentic AI platform built on multimodal biological data — including genomics, histopathology imaging, and clinical outcomes — and fine-tuned language models the company calls biological reasoning models. Unlike general-purpose AI tools, the platform is designed to execute multi-step scientific reasoning tasks autonomously, decomposing complex research questions and synthesizing outputs across data sources restricted to credible scientific literature. Owkin positions this architecture as distinct from retrieval-augmented generation approaches, characterizing K Pro as capable of active workflow orchestration rather than text retrieval alone.

Under the agreement, Owkin leads end-to-end development of the AI agents, which will run on K Pro and operate within AstraZeneca's governance and security frameworks. The agents are intended to reduce reliance on manual analysis for competitive intelligence questions across AstraZeneca's portfolio. The scope is enterprise-wide rather than indication-specific, covering any program where competitive landscape analysis or target forecasting is relevant.

The deal extends a prior working relationship between the two companies. Owkin and AstraZeneca previously collaborated on an AI-based germline BRCA pre-screening tool for breast cancer, with results presented at ESMO 2025 showing the BRCAura solution ruled out approximately 40% of patients unlikely to carry gBRCA mutations at 93% sensitivity. That diagnostic work has since been transferred to Waiv, a spin-out of Owkin's diagnostics division, while Owkin's core operations refocus on the K Pro platform.

Industry and transaction context

The agreement reflects a pattern of AstraZeneca sourcing AI platform capabilities through multi-year licensing arrangements rather than acquisitions or equity stakes. In September 2025, SOPHiA GENETICS expanded its AI collaboration with AstraZeneca to cover breast and prostate cancer detection, and in January 2025, Synthego entered a strategic licensing agreement with AstraZeneca covering CRISPR gene editing enzyme access. The K Pro deal follows a similar structure — time-limited access with a service or build component — consistent with AstraZeneca treating external AI platforms as infrastructure inputs rather than pipeline assets.

The deal's vendor-led build-and-integrate model, where Owkin develops agents to specification within AstraZeneca's environment, is structurally closer to an enterprise software services arrangement than a traditional biopharma licensing transaction. This structure has become more common as large pharma companies seek to embed AI capabilities without taking on platform development risk internally, while AI vendors seek anchor enterprise customers to validate commercial deployment at scale.

---

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

---

Spot something wrong? Report an issue with this article